Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2012 by Innovative Medical.
Recruitment status was:  Recruiting
Information provided by:
Innovative Medical Identifier:
First received: June 24, 2011
Last updated: June 13, 2012
Last verified: June 2012
The purpose of this study is to evaluate and compare the effects of Altaire Gel forming solution and Refresh Tears in mild-moderate dry eye patients.

Condition Intervention Phase
Dry Eye Syndromes
Drug: Altaire Gel forming solution
Drug: Refresh Tears
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms

Resource links provided by NLM:

Further study details as provided by Innovative Medical:

Primary Outcome Measures:
  • TBUT [ Time Frame: 2 months ]
    Test performed that measures how long the tears take to break up

  • Conjunctival and Corneal staining [ Time Frame: 2 months ]
    Dye that will be placed inside the eye to evaluate the surface of the ey

Estimated Enrollment: 100
Study Start Date: March 2011
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Altaire Gel forming solution Drug: Altaire Gel forming solution
Three times a day for two months
Placebo Comparator: Refresh Tears Drug: Refresh Tears
Three times a day for two months


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients 18 years or older.
  • Males or females.
  • Patient reported dry eye symptoms (episodic, annoying, activity limiting).
  • Physician assessment of mild-moderate dry eye.
  • Patient willing to instill drops TID and complete entire length of protocol.
  • TBUT _< 10 seconds.
  • At least Grade 6 Corneal Staining.

Exclusion Criteria:

  • Current topical cyclosporine use (Restasis)
  • Current Refresh use.
  • Refractive surgery within the last 6 months.
  • Oral or topical corticosteroid use.
  • Severe dry eye patients by physician assessment.
  • Current active blepharitis.
  • Oral doxycycline use.
  • Oral antihistamine use.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01382810

Contact: Jenna Piel 951-653-5566

United States, Illinois
Jackson Eye, SC Recruiting
Lake Villa, Illinois, United States
Contact: Annie Christensen    951-653-5566   
Principal Investigator: Mitch Jackson, MD         
United States, Rhode Island
Koch Eye Associates Recruiting
Warwick, Rhode Island, United States
Contact: Annie Christensen    951-653-5566   
Principal Investigator: Paul Koch, MD         
Sponsors and Collaborators
Innovative Medical
  More Information

Responsible Party: Melissa Earl, CRO Identifier: NCT01382810     History of Changes
Other Study ID Numbers: Altaire2011
Study First Received: June 24, 2011
Last Updated: June 13, 2012

Keywords provided by Innovative Medical:
dry eye signs and symptoms

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Signs and Symptoms
Conjunctival Diseases
Eye Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Pharmaceutical Solutions processed this record on May 25, 2017